Figure 5
![Figure 5. MKC-3946 enhances MM cytotoxicity of bortezomib or 17-AAG, even in the presence of BMSCs or exogenous IL-6. (A-B) INA6 cells were treated with bortezomib (A) or 17-AAG (B) in combination with MKC-3946 0μM (□), 5μM (▩), or 10μM (■), in the presence or absence of BMSCs for 48 hours. (C-D) INA6 cells were treated with bortezomib (C) or 17-AAG (D) in combination with MKC-3946 0μM (□), 5μM (▩), or 10μM (■), with 2.5 ng/mL or 10 ng/mL of IL-6 for 48 hours. Cell proliferation was assessed by [3H]-thymidine uptake of quadruplicate cultures. Data represent the mean ± SD of [3H]-thymidine incorporation (CPM).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/119/24/10.1182_blood-2011-07-366633/5/zh89991292210005.jpeg?Expires=1722705541&Signature=CcSR5gAMEp1uEwSWdcsDtvlZAipMEz3EJhY2ZkZMFoV2teXXrBTtF00VEvHoHK62GzSfpaTdUpTlGgD3yvTSScl~-EtC2CQsUf6SNL52PijfKeetuKEmR017IeqlN93dqFHctlEChMJSHorTgDJAkNE2k-oKw9DQnxy3elkFID73YQ5YuP5OAAVHL~3l0BQl7lk2Ric8XfHG0q95CJycZ98Bni0NHvVxmWYjHa~MfOtfc55XEU1cROwiQC0UTJx7WEn3m-EWvegMYgnViLrh-gRsvhQdUR-3PtQETuFC9ZwBRoebA6U~Uv6tVt0I4PnGwyuprAZn~dGS9BhC39gLDA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
MKC-3946 enhances MM cytotoxicity of bortezomib or 17-AAG, even in the presence of BMSCs or exogenous IL-6. (A-B) INA6 cells were treated with bortezomib (A) or 17-AAG (B) in combination with MKC-3946 0μM (□), 5μM (▩), or 10μM (■), in the presence or absence of BMSCs for 48 hours. (C-D) INA6 cells were treated with bortezomib (C) or 17-AAG (D) in combination with MKC-3946 0μM (□), 5μM (▩), or 10μM (■), with 2.5 ng/mL or 10 ng/mL of IL-6 for 48 hours. Cell proliferation was assessed by [3H]-thymidine uptake of quadruplicate cultures. Data represent the mean ± SD of [3H]-thymidine incorporation (CPM).
